



Supported by  
**octapharma**<sup>®</sup>  
For the safe and optimal use of human proteins

*This educational course and U.S. attendee travel, lodging and registration is supported by Octapharma and the course is offered in collaboration with the Malmö Centre for Thrombosis and Haemostasis, Lund University, and Skåne University Hospital*



## **ITI School in Hemophilia 2020 Award Recipient**



### **Clay Cohen, MD, Instructor**

**Baylor College of Medicine/Texas Children's Hospital**

**Mentor: Donald H. Mahoney, MD**

**Course Title: "ITI School in Hemophilia" in Malmö, Sweden**

**Dr. Clay Cohen received his Bachelor of Science Degree in Biology from Furman University and his medical degree from the University of Texas-Houston Medical School. Dr. Cohen completed his residency training in Pediatrics and Chief Resident year at the University of Alabama-Birmingham/Children's of Alabama, and fellowship training in Pediatric Hematology and Oncology at Baylor College of Medicine/Texas Children's Hospital in Houston, Texas. He is currently an Assistant Professor at Baylor College of Medicine/Texas Children's Hospital. As a pediatric hematologist, he is**

**an active member of the clinical hemostasis and thrombosis team, treating children with bleeding and thrombotic disorders, as well as general hematological issues, in both inpatient and outpatient settings. Dr. Cohen also performs basic research evaluating the role of endothelial cells and the vascular wall in human coagulation. From the ITI Workshop, he took away the continued importance of immune tolerance in hemophilia even with the emergence of emicizumab, and how both therapies can be combined for hemophilia patients with inhibitors.**